Scholarlink

Background <p>Locally advanced rectal cancer (LARC) represents a pivotal stage of rectal cancer where it is possible to completely cure the cancer before its systemic spread, thus often requiring an aggressive multimodal therapy. Recent trials suggest that programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors combined with neoadjuvant chemoradiotherapy (CRT) may improve treatment outcomes. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors when integrated into neoadjuvant CRT regimens for LARC patients.</p> Methods <p>A systematic search of PubMed, Embase, ClinicalTrials.gov, and Cochrane Central Library was conducted up to October 11, 2024. Randomized controlled trials (RCTs) comparing neoadjuvant CRT with or without PD-1/PD-L1 inhibitors were included. The primary outcomes assessed were pathological complete response (pCR), clinical complete response (cCR), and serious adverse events (SAEs). Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Subgroup analyses were performed to explore variations in radiotherapy strategies, types of PD-1/PD-L1 inhibitors used, and mismatch repair (MMR) status.</p> Results <p>Six RCTs (861 patients) met the inclusion criteria. PD-1 inhibitors significantly improved pCR rates (OR = 2.10, 95% CI: 1.32–3.32, <i>p</i> = 0.001), particularly with short-course radiotherapy (SCRT) and agents like Camrelizumab and Tislelizumab. However, PD-1 inhibitors did not significantly enhance cCR (OR = 1.54, 95% CI: 0.51–4.63, <i>p</i> = 0.44) or increase SAEs (OR = 1.08, 95% CI: 0.73–1.60). Subgroup analysis based on MMR status revealed a significantly higher pCR rate in the proficient MMR (pMMR) subgroup compared to the deficient MMR (dMMR) subgroup, although the result for dMMR was non-significant due to limited sample size and the absence of reported events.</p> Conclusions <p>The addition of PD-1 inhibitors to neoadjuvant CRT significantly improves pCR rates in LARC without increasing toxicity. These findings support their potential role in standard treatment protocols, warranting further phase III trials.</p> Registration number <p>CRD42024619949.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neoadjuvant chemoradiotherapy with or without PD-1/PD-L1 inhibitors in locally advanced rectal cancer: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Muhammad Ansab,
  • Sepideh Razi,
  • Farwa Nisa,
  • Eiman Araib,
  • Shree Rath,
  • Iqra Khan,
  • Noor Ul Huda Ramzan,
  • Esha Dilawar,
  • Anwaar Saeed

摘要

Background

Locally advanced rectal cancer (LARC) represents a pivotal stage of rectal cancer where it is possible to completely cure the cancer before its systemic spread, thus often requiring an aggressive multimodal therapy. Recent trials suggest that programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors combined with neoadjuvant chemoradiotherapy (CRT) may improve treatment outcomes. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors when integrated into neoadjuvant CRT regimens for LARC patients.

Methods

A systematic search of PubMed, Embase, ClinicalTrials.gov, and Cochrane Central Library was conducted up to October 11, 2024. Randomized controlled trials (RCTs) comparing neoadjuvant CRT with or without PD-1/PD-L1 inhibitors were included. The primary outcomes assessed were pathological complete response (pCR), clinical complete response (cCR), and serious adverse events (SAEs). Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Subgroup analyses were performed to explore variations in radiotherapy strategies, types of PD-1/PD-L1 inhibitors used, and mismatch repair (MMR) status.

Results

Six RCTs (861 patients) met the inclusion criteria. PD-1 inhibitors significantly improved pCR rates (OR = 2.10, 95% CI: 1.32–3.32, p = 0.001), particularly with short-course radiotherapy (SCRT) and agents like Camrelizumab and Tislelizumab. However, PD-1 inhibitors did not significantly enhance cCR (OR = 1.54, 95% CI: 0.51–4.63, p = 0.44) or increase SAEs (OR = 1.08, 95% CI: 0.73–1.60). Subgroup analysis based on MMR status revealed a significantly higher pCR rate in the proficient MMR (pMMR) subgroup compared to the deficient MMR (dMMR) subgroup, although the result for dMMR was non-significant due to limited sample size and the absence of reported events.

Conclusions

The addition of PD-1 inhibitors to neoadjuvant CRT significantly improves pCR rates in LARC without increasing toxicity. These findings support their potential role in standard treatment protocols, warranting further phase III trials.

Registration number

CRD42024619949.